As­cendis spins out oph­thal­mol­o­gy com­pa­ny; Gami­da Cell eyes strate­gic op­tions

Plus, news about Skye Bio­science and Ve­ra Ther­a­peu­tics:

As­cendis Phar­ma, in­vestors spin out eye care com­pa­ny: Ey­co­nis, based in Red­wood City, CA, will de­vel­op, man­u­fac­ture and com­mer­cial­ize the com­pa­ny’s oph­thal­mol­o­gy as­sets, as pre­vi­ous­ly dis­closed. The in­vestor group in­cludes Fra­zier Life Sci­ences, RA Cap­i­tal Man­age­ment, ven­Bio and HealthQuest Cap­i­tal. As­cendis has grant­ed Eye­co­nis the rights to de­vel­op and com­mer­cial­ize its eye care prod­ucts, and the Dan­ish drug­mak­er can al­so re­ceive mile­stones up to $248 mil­lion, plus sin­gle-dig­it roy­al­ty on prod­uct sales. “Be­cause of the broad ap­plic­a­bil­i­ty of the tech­nol­o­gy plat­form, po­ten­tial­ly some of this el­e­ment are much bet­ter man­aged in ac­cel­er­a­tion where there is a ded­i­cat­ed, high lev­el, high knowl­edge­able oph­thal­mol­o­gy lead­er­ship,” CEO Jan Mikkelsen told in­vestors at the JP Mor­gan Health­care Con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER